Discover
HELP
Cybin D/B/A Helus Pharma
6.28
2 x 4.68
2 x 8.23
bid
ask
-
0.33
4.99%
2 @ 04:00 PM
6.36 +0.08 (1.27%)
| Ytd | -23.23% | |
| 1y | -30.22% |
6.26
day range
6.63
3.76
52 week range
9.16
| Open | 6.51 | Prev Close | 6.61 | Low | 6.26 | High | 6.63 | Mkt Cap | 389.32M |
| Vol | 1.08M | Avg Vol | 1.19M | EPS | -4.25 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.94 | 200-d Avg | 5.98 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 41.21M | ||
| Research and Development Expense | 23.86M | ||
| Selling, General and Administrative Expense | 12.88M | ||
| Operating Income | -41.21M | ||
| Net Income | -42.67M | ||
| Net Income Common Stock | -42.67M | ||
| Net Income Common Stock (USD) | -31.14M | ||
| Consolidated Income | -42.67M | ||
| Earnings per Basic Share | -1.00 | ||
| Earnings per Basic Share (USD) | -0.73 | ||
| Earnings per Diluted Share | -1.00 | ||
| Earning Before Interest & Taxes (EBIT) | -42.67M | ||
| Earning Before Interest & Taxes (USD) | -31.14M | ||
| Weighted Average Shares | 42.52M | ||
| Weighted Average Shares Diluted | 42.52M | ||
| Balance Sheet | |||
| Cash and Equivalents | 195.13M | ||
| Cash and Equivalents (USD) | 142.43M | ||
| Trade and Non-Trade Receivables | 4.77M | ||
| Current Assets | 222.90M | ||
| Property, Plant & Equipment Net | 186.00K | ||
| Total Assets | 290.11M | ||
| Current Liabilities | 16.18M | ||
| Total Liabilities | 16.18M | ||
| Accumulated Retained Earnings (Deficit) | -342.54M | ||
| Accumulated Other Comprehensive Income | 867.00K | ||
| Shareholders Equity | 273.93M | ||
| Shareholders Equity (USD) | 199.95M | ||
| Assets Non-Current | 67.22M | ||
| Goodwill and Intangible Assets | 67.03M | ||
| Trade and Non-Trade Payables | 16.18M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 22.00K | ||
| Net Cash Flow from Financing | 143.75M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 111.38M | ||
| Capital Expenditure | -383.00K | ||
| Issuance (Purchase) of Equity Shares | 164.02M | ||
| Issuance (Repayment) of Debt Securities | -20.15M | ||
| Net Cash Flow from Investing | -383.00K | ||
| Net Cash Flow from Operations | -31.95M | ||
| Effect of Exchange Rate Changes on Cash | -42.00K | ||
| Share Based Compensation | 4.48M | ||